The Company
GenScript ProBio is a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) specializing in providing comprehensive antibody and gene therapy development services. Their offerings include cell line development, GMP manufacturing, and regulatory support, ensuring a streamlined pathway from discovery to commercialization. To make life-changing therapies available to everyone worldwide, GenScript ProBio partners with clients to accelerate the development of novel therapeutics to enhance the state of global healthcare.
The Challenge
Before AlphaSense, GenScript ProBio’s Head of Marketing – Americas and Europe, Alvin Jogasuria, described his research processes as manual and time-consuming. He spent each week laboriously compiling multiple RSS feeds and checklists to summarize industry trends and company updates. “These manual processes were very labor-intensive because they require an analyst to diligently monitor company updates across various reports and try to summarize the relevant information weekly,” comments Jogasuria. The team would spend additional time vetting 3rd party companies to perform market research, putting them 4-8 weeks behind in their diligence deliverables.
Streamlining Research Time With Generative AI
Jogasuria invested in AlphaSense to streamline his workflows and make more confident decisions. Compared to other vendors investigated, AlphaSense “stood out from the competition” given the user-friendly feature suite. Specifically, Jogasuria highlights AlphaSense’s Smart Summaries feature, which helps “provide up-to-date summaries on company data and quarterly industry reports.” Access to a platform that can parse a large data set into digestible summaries has allowed him to focus on repurposing the insights into informed, confident decisions.
“As a market analyst, AlphaSense really helps me dig deeper and get actionable insights as quickly as possible.”
– Alvin Jogasuria, Head of Marketing – Americas and Europe, GenScript ProBio
Moreover, Jogasuria emphasizes the significant time and cost savings he has experienced as a result of investing in AlphaSense. With AlphaSense, he is able to surface the information he needs within a single session spent using the platform rather than the months it used to take to get the same information from a third-party analyst. Jogasuria claims that this rapid discovery of information on competitor trends and industry insights is pivotal to helping GenScript ProBio achieve its short- and long-term goals on the pathway to becoming a leading global CDMO.
“With AlphaSense, you have accelerated discovery that traditionally takes six months into less than two weeks, and with that very fast cadence you’re able to really drive your business forward.”
We connected with Jogasuria at BIO International in June 2024 to capture his story live on camera. Watch the short video to learn more about how GenScript ProBio leverages AlphaSense to accelerate discovery and make faster, smarter decisions.
Get started today
The world’s leading corporations and financial institutions—including a majority of the S&P 500, over 85% of the S&P 100, and 75% of the top asset management firms—trust AlphaSense for smarter, faster decisions.
Start my free trial
